Clinical practices and outcomes of RhD immunoglobulin prophylaxis following large-volume fetomaternal haemorrhage in Queensland, Australia.
RhD immunoglobulin
alloimmunisation
fetomaternal haemorrhage
Journal
The Australian & New Zealand journal of obstetrics & gynaecology
ISSN: 1479-828X
Titre abrégé: Aust N Z J Obstet Gynaecol
Pays: Australia
ID NLM: 0001027
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
06
01
2020
accepted:
30
06
2020
pubmed:
14
8
2020
medline:
26
5
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Guidelines for laboratory assessment of fetomaternal haemorrhage (FMH) was published by the Australian and New Zealand Society of Blood Transfusion (ANZSBT) in 2002. However, data on adherence by practitioners and clinical outcomes are lacking. The primary objective is to examine the follow-up testing and dosing of additional RhD immunoglobulin in RhD negative women who experienced large-volume FMH for whom additional intravenous RhD immunoglobulin was requested in Queensland, Australia. The secondary objectives are to examine the rate and risk factors of RhD alloimmunisation in these women. RhD negative women with FMH >6 mL for whom additional dose(s) of intravenous RhD immunoglobulin was requested through Australian Red Cross Lifeblood from February 2007 to February 2018 were identified. For each patient, the volume of FMH, methods and timing of FMH quantitation, dose of RhD immunoglobulin, maternal and cord blood groups were analysed against the corresponding antibody screen and identification. Following FMH >6 mL, only 15% and 11.5% of cases adhered to current ANZSBT guideline on follow-up testing and supplemental RhD immunoglobulin dosing respectively. Despite the provision of single supplemental RhD immunoglobulin at a ratio of 100 IU to 1 mL fetal red cells, the rate of RhD alloimmunisation in RhD negative women with RhD positive fetus or fetus of unknown RhD status following FMH >6 mL is at least 4%. Poor compliance with guidelines for follow-up and management of large-volume FMH may contribute to increased risk of RhD alloimmunisation. Further analysis of data is warranted.
Sections du résumé
BACKGROUND
Guidelines for laboratory assessment of fetomaternal haemorrhage (FMH) was published by the Australian and New Zealand Society of Blood Transfusion (ANZSBT) in 2002. However, data on adherence by practitioners and clinical outcomes are lacking.
AIMS
The primary objective is to examine the follow-up testing and dosing of additional RhD immunoglobulin in RhD negative women who experienced large-volume FMH for whom additional intravenous RhD immunoglobulin was requested in Queensland, Australia. The secondary objectives are to examine the rate and risk factors of RhD alloimmunisation in these women.
MATERIALS AND METHODS
RhD negative women with FMH >6 mL for whom additional dose(s) of intravenous RhD immunoglobulin was requested through Australian Red Cross Lifeblood from February 2007 to February 2018 were identified. For each patient, the volume of FMH, methods and timing of FMH quantitation, dose of RhD immunoglobulin, maternal and cord blood groups were analysed against the corresponding antibody screen and identification.
RESULTS
Following FMH >6 mL, only 15% and 11.5% of cases adhered to current ANZSBT guideline on follow-up testing and supplemental RhD immunoglobulin dosing respectively. Despite the provision of single supplemental RhD immunoglobulin at a ratio of 100 IU to 1 mL fetal red cells, the rate of RhD alloimmunisation in RhD negative women with RhD positive fetus or fetus of unknown RhD status following FMH >6 mL is at least 4%.
CONCLUSIONS
Poor compliance with guidelines for follow-up and management of large-volume FMH may contribute to increased risk of RhD alloimmunisation. Further analysis of data is warranted.
Substances chimiques
Immunoglobulins
0
Rho(D) Immune Globulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-212Informations de copyright
© 2020 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Références
Pollack W, Ascari WQ, Kochesky RJ et al. Studies on Rh prophylaxis I. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion 1971; 11(6): 333-339.
Pollack W, Ascari WQ, Crispen JF, et al. Studies on Rh prophylaxis II. Rh immune prophylaxis after transfusion with Rh-positive blood. Transfusion 1971; 11(6): 340-344.
Scientific Subcommittee of the Australian & New Zealand Society of Blood Transfusion Inc. Guidelines for Laboratory Assessment of Fetomaternal Haemorrhage [Internet]. Sydney, NSW: Australian & New Zealand Society of Blood Transfusion; 2002. Available from URL https://anzsbt.org.au/wp-content/uploads/2018/06/ANZSBTguide_Nov02a.pdf
National Health and Medical Research Council (AU). Guidelines on the Prophylactic Use of Rh D Immunoglobulin (anti-D) in Obstetrics [Internet]. Canberra, ACT: National Health and Medical Research Council (AU); 2003. Available from URL https://www.blood.gov.au/system/files/documents/glines-anti-d.pdf
Transfusion Science Standing Committee Australian & New Zealand Society of Blood Transfusion Ltd. Guidelines for transfusion and immunohaematology laboratory practice, 1st edn., [Internet]. Sydney, NSW: Australian & New Zealand Society of Blood Transfusion; 2016. Available from URL https://anzsbt.org.au/wp-content/uploads/2018/06/GuidelinesforTransfusionandImmunohaematologyLaboratoryPractice_1ed_Nov20_.pdf
Working Party of the British Committee for Standards in Haematology, Transfusion Taskforce. Guidelines for the estimation of fetomaternal haemorrhage [Internet]. London: British Committee for Standards in Haematology; 2009. Available from URL https://b-s-h.org.uk/media/15705/transfusion-austin-the-estimation-of-fetomaternal-haemorrhage.pdf
Qureshi H, Massey E, Kirwan D et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014; 24: 8-20.
Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 181: prevention of Rh D alloimmunization. Obstet Gynecol 2017; 130(2): e57-e70.
Fung KFK, Eason E. No. 133-Prevention of Rh Alloimmunization. J Obstet Gynaecol Can 2018; 40: 1-10.
David M, Smidt J, Chen FC, et al. Risk factors for fetal-to-maternal transfusion in Rh D-negative women - results of a prospective study on 942 pregnant women. J Perinat Med 2004; 32(3): 254-257.
De Almeida MV, Bowman MJ. Massive fetomaternal hemorrhage: Manitoba experience. Obstet Gynecol 1994; 83(3): 323-328.
Koelewijn JM, de Haas M, Vrijkotte TGM, et al. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116(10): 1307-1314.
Lubenko A, Williams M, Johnson A et al. Monitoring the clearance of fetal RhD positive red cells in FMH, following anti-D immunoglobulin administration. Transfus Med 1999; 9(4): 331-335.
Nevanlinna HR, Vainio T. The influence of mother-child ABO incompatibility on Rh immunisation. Vox Sang 1956; 1: 26-36.
Karafin MS, Westlake M, Hauser RG et al. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. Br J Haematol 2018; 181(5): 672-681.
Augustson BM, Fong EA, Grey DE et al. Postpartum anti-D: can we safely reduce the dose? Med J Aust 2006; 184: 611-613.
Department of Health and Human Services, State of Victoria (AU). RhD Immunoglobulin in Obstetrics Audit Report 2018 [Internet]. Melbourne, Vic: Victorian Government; 2019. Available from URL https://www2.health.vic.gov.au/hospitals-andhealthservices/patient-care/speciality-diagnostics-therapeutics/blood-matters